Dyslipidemia is characterized by increased triglyceride
and low-density lipoprotein (LDL) levels, and decreased high-density
lipoprotein (HDL) levels. Such an atherogenic lipid profile often
predisposes an at risk individual to coronary artery disease with
incompletely understood mechanisms. Apolipoprotein D (apoD) is an atypical
apolipoprotein. Unlike canonical apolipoproteins that are produced mainly
in liver and intestine, apoD is expressed widely in mammalian tissues. ApoD
does not share significant degrees of homology in amino acid sequence with
other apolipoproteins. Instead, apoD is structurally similar to lipocalins,
a diverse family of lipid-binding proteins that are responsible for
transporting lipids and other small hydrophobic molecules for metabolism.
Plasma ApoD is present mainly in HDL and to a lesser extent in low density
lipoproteins (LDL) and very low-density lipoproteins (VLDL). Genetic
variants of apoD are associated with abnormal lipid metabolism and
increased risk of developing metabolic syndrome. Increased apoD deposition
is detectable in atherosclerotic lesions of humans with established
cardiovascular disease as well as mice with premature atherosclerosis.
Moreover, apoD is associated with anti-oxidation and anti-stress
activities, contributing to lifespan expansion in fruit flies. Elderly
subjects and patients with Alzheimer exhibit markedly elevated apoD
production in the brain. Thus, apoD is emerged as a significant player in
lipid metabolism and aging. Here we focus our review on recent advances
toward our understanding of apoD in lipid metabolism and address whether
apoD dysregulation contributes to the pathogenesis of dyslipidemia and
atherosclerosis. We will also discuss the functional implication of apoD in
aging.